Stock·NASDAQ·Healthcare
Vertex Pharmaceuticals Incorporated (VRTX)
- Market cap
- $131.08B
- P/E
- 30.14
- Dividend yield
- None
- Street target
- $578.00median of 32 analysts
- 52-week range
- $403.16 $560.25
VRTX stock forecast today
Where VRTX stands today, and what CleaRank Financial AI makes of it.
VRTX at a glance
Vertex Pharmaceuticals Incorporated (VRTX): Buy, 68/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($477.61 and $522.94).
- Earnings VRTX beat estimates in 3 of its last 7 quarters, yet fell the next day after every one of them.
- Insiders Insiders sold $157.5M and bought $5.8M over the last 18 months.
- Valuation P/E of 30.1 against 31.9 for the Healthcare sector: broadly in line with peers (-6%).
Figures as of October 26, 2026.
CleaRank Financial AI
VRTX, or Vertex Pharmaceuticals Incorporated, receives a CleaRank rating of Buy with a model score of 68/100.
Its strongest factor is the trend, with the price 8.35% above its 200-day average and the 50-day average 9.49% above the 200-day. Valuation pulls the score down the most, as the P/S of 10.41 sits 206.2% above the sector median. The 50-day average is $522.94 and the 200-day is $477.61. The price has risen 22.81% over the past year.
Only on CleaRank
Figures we compute ourselves from VRTX's own price, earnings and insider-filing history. Tap one to see it in context.
VRTX stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $517.49 is 1.0% below the 50-day simple moving average of $522.94.Price above its 200-day average ›
The price is 8.4% above the 200-day simple moving average of $477.61.50-day average above the 200-day ›
The 50-day average ($522.94) is 9.5% above the 200-day average ($477.61), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 73% of its 52-week range, between $403.16 and $560.25.
VRTX share price
Pick a period: each tab shows how far VRTX has moved over it, to the last close.
Today's trading
Where VRTX sits inside today's range and its 52-week range.
VRTX fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/E below the sector median ›
The trailing P/E of 30.14 is 5.5% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 10.41 is 206.3% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $4.4B on revenue of $12.6B, a net margin of 35.0%.Beat estimates in most recent reports ›
VRTX beat the EPS estimate in 3 of its last 7 reports.
Key statistics
The headline figures for VRTX.
As of October 26, 2026, VRTX trades at $517.49, with a market value of $131.08B and a P/E ratio of 30.14.
What the numbers say
CleaRank Financial AI's reading of VRTX's valuation, growth and risks.
Vertex Pharmaceuticals Incorporated (VRTX) trades on a trailing P/E of 30.14, which is 5.5% below the Healthcare median of 31.9. The peer comparison on this page rates that as broadly in line with peers. On price-to-sales, the 10.41 ratio is 206.2% above the sector median of 3.4. Its market capitalisation stands at $131.1B.
VRTX is growing faster than its sector. Revenue rose 12.50% year on year in the latest quarter, while the sector median stands at 8.1%. The company converts sales into profit well, with a net margin of 35.00% and an operating margin of 38.06%. Its return on equity of 23.54% sits above the sector median of 7.3%, and its debt-to-equity ratio is 0.10.
VRTX reported its latest quarter on August 3, 2026, with EPS of $4.73 against the $4.75 analysts had forecast, so it missed the estimate by 0.42%. Despite the shortfall, the share price climbed 1.70% in the next session.
The earnings record shows 3 beats in 7 reports, yet the stock fell in the first session after every one of those 3 beats. The February 12, 2026 report stands out among the few before the latest: a miss of 2.33%, after which the stock rose 5.69%. Looking ahead, analysts expect EPS of $17.88 this fiscal year (a decline of 2.8%) and $20.34 the year after (growth of 13.8%).
VRTX typically moves about 1.58% on a given day, and its beta against the S&P 500 is 0.28. Over the last 18 months, insiders sold $157.5M of stock and bought $5.8M. Insider sales are often planned ahead or made to cover taxes on vesting shares, so they tell less than open-market purchases would.
VRTX against the Healthcare sector
How VRTX compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (-6% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 14, 2025, VRTX has gained 22.9% against a gain of 39.2% for XLV.
Performance against XLV
VRTX and the Healthcare sector fund over the same days.
Revenue and earnings
How much VRTX sells, and how much of it becomes profit.
Revenue growth: Revenue grew 8.9% in FY2025 to $12.0B, from $11.0B a year earlier.
Profit margin: The net margin was 32.9% in FY2025, up from -4.9% the year before.
Profitable: VRTX earned $4.0B in FY2025.
Earnings reality check
Did VRTX beat what analysts expected, and how did the stock react?
Earnings record: VRTX beat the analyst estimate in 3 of the last 7 quarters.
Market reaction: The stock fell in the first session after 3 of those 3 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 3, 2026after close | $4.75 | $4.73 | -0.42% | +1.70% | +11.30% |
| May 4, 2026after close | $4.31 | $4.47 | +3.71% | -1.28% | +1.24% |
| Feb 12, 2026after close | $5.15 | $5.03 | -2.33% | +5.69% | +2.55% |
| Nov 3, 2025after close | $4.58 | $4.80 | +4.80% | -1.02% | -1.13% |
| Aug 4, 2025after close | $4.25 | $4.52 | +6.35% | -20.60% | -20.71% |
| May 5, 2025after close | $4.29 | $4.06 | -5.36% | -10.03% | -12.16% |
| Feb 10, 2025after close | $4.02 | $3.98 | -1.00% | -3.14% | -1.67% |
As of October 26, 2026, VRTX has beaten the analyst EPS estimate in 3 of its last 7 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on August 3, 2026, came in 0.42% below the estimate and the stock moved +1.70% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
VRTX AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 51.7, in neutral territory.RSI above 50 ›
An RSI of 51.7 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of VRTX
The score, the reasoning behind it, and what could move the price next.
VRTX sends a mixed trend signal: at $517.49, it trades 1.04% below its 50-day average of $522.94 but 8.35% above its 200-day average of $477.61. The price sits near the top of its 52-week range, 7.63% below the high of $560.25 and 28.36% above the low of $403.16. With the 50-day average 9.49% above the 200-day, the averages have not yet caught up with the weaker price.
The recent pullback sits within a longer run of gains. Over the past month the price slipped 1.65%, yet it climbed 8.04% over three months and 22.81% over the past year. The 14-day RSI of 51.7 places the stock in the neutral zone, and the MACD line is positive.
Earnings miss, but the stock rose ›
The August 3, 2026 report missed the EPS estimate by 0.42%, and the share price rose 1.70% in the first session after it.
Source: Earnings report, August 3, 2026New analyst coverage ›
JP Morgan restarted coverage at Overweight on September 11, 2026.
Source: Analyst action, JP Morgan, September 11, 2026New analyst coverage ›
Morgan Stanley restarted coverage at Overweight on September 2, 2026.
Source: Analyst action, Morgan Stanley, September 2, 2026
- Keep an eye on the two closest levels: the 50-day SMA at $522.94 sits above the price, and the 20-day EMA at $513.94 sits below it.
- The 14-day RSI reads 51.7, in the neutral zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- After the August 3, 2026 report the share price rose 1.70% in the first session; VRTX beat estimates in 3 of the last 7 reports.
The trend is mixed: VRTX is above its 200-day average at $477.61 but below its 50-day average at $522.94. A close above the 50-day would turn both signals up, and a close below the 200-day would turn both down. The nearest levels are the 20-day EMA at $513.94 below and the 50-day SMA at $522.94 above.
Technical indicators
Momentum and trend for VRTX, from its daily closes.
As of October 26, 2026, with VRTX at $517.49, its 14-day RSI is 51.7 (neutral territory), its 50-day simple moving average is $522.94 and its 200-day is $477.61.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What VRTX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, VRTX's 1-year correlation of daily returns is +0.24 with S&P 500 (SPY), +0.18 with Nasdaq 100 (QQQ), +0.20 with Bitcoin (BTC) and +0.10 with gold (XAU).
VRTX price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
26 of 32 analysts rate it a buy or strong buy, 5 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $578.00 is 11.7% above the price.More buy ratings than three months ago ›
26 of 32 rate it a buy now, against 23 of 29 three months ago.
VRTX Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Maintains | Outperform |
| Sep 28, 2026 | UBS | Maintains | Buy |
| Sep 11, 2026 | JP Morgan | Reinstates | Overweight |
| Sep 2, 2026 | Morgan Stanley | Reinstates | Overweight |
| Aug 5, 2026 | Truist Securities | Maintains | Buy |
| Aug 5, 2026 | Barclays | Maintains | Overweight |
As of October 26, 2026, 32 Wall Street analysts cover VRTX: 26 rate it a buy or strong buy, 5 a hold and 1 a sell or strong sell. Their 12-month price targets range from $350.00 to $667.00. The median VRTX price target is $578.00, 11.7% above the price of $517.49.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
VRTX trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
VRTX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from VRTX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much VRTX tends to move, against the market and on its own.
VRTX price history and drawdowns
VRTX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.58% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 39.4%, from June 2020 to October 2021, regained by August 2022.Most 1-year holds ended higher ›
76% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $68,234, against $42,015 in the S&P 500 (SPY).
VRTX Drawdowns & Recovery
As of October 26, 2026, VRTX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -39.4% (June 2020 to October 2021); it regained that peak by August 2022, 10 months after the low, and 76% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into VRTX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: VRTX beat the S&P 500 over this period: $68,234 against $42,015.
A $10,000 investment in VRTX in October 2016 would be worth about $68,234 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to VRTX, and which have not.
Strongest month, January: an average of +7.54%, up in 9 of 10 years.
Weakest month, September: an average of -1.99%, up in 3 of 10 years.
This month, October: has averaged -0.10%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, VRTX's strongest calendar month has been January (average +7.54%, up in 9 of 10 years) and its weakest September (average -1.99%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
VRTX stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in VRTX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in VRTX today could grow to about $14,870 by 2030 in the base case, with a 90th-percentile outcome near $34,318 and a 10th-percentile outcome around $6,443. Projections are statistical simulations, not guarantees.
VRTX Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $770 for VRTX by 2030 in the base case, from $517 today (1.5x over 4 years). The 10th-percentile path ends near $333. These are outcomes of a Monte Carlo simulation run on VRTX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $376 | $571 | $868 | |
| 2028 | $349 | $631 | $1,140 | |
| 2029 | $338 | $697 | $1,438 | |
| 2030 | $333 | $770 | $1,776 |
Method: a lognormal simulation of VRTX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
VRTX insider trading
What the people running the company have bought and sold.
VRTX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $5.8M on the open market and sold $157.5M.
As of October 26, 2026, VRTX insiders reported 55 open-market sales worth $157.5M and 2 open-market purchases worth $5.8M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 28, 2026 | Kristen Ambrose
Officer
|
Grant | 5.0K | - |
| Aug 27, 2026 | Bruce I Sachs
Director
|
Grant | 6.0K | - |
| Jul 21, 2026 | Amit Sachdev
Officer
|
Grant | 8.3K | - |
| Jul 21, 2026 | Ourania Tatsis
Officer
|
Grant | 8.3K | - |
| Jul 2, 2026 | Duncan J. Mckechnie
Officer
|
Sell | 1.5K | $799.8K |
| Jul 2, 2026 | Ourania Tatsis
Officer
|
Sell | 1.5K | $787.5K |
| Jul 1, 2026 | Joy Liu
Officer
|
Sell | 828 | $416.2K |
| Jun 26, 2026 | Carmen Bozic
Officer
|
Sell | 596 | $287.6K |
| Jun 18, 2026 | Carmen Bozic
Officer
|
Sell | 1.0K | $471.4K |
| Jun 15, 2026 | Carmen Bozic
Officer
|
Sell | 4.1K | $1.8M |
| Jun 5, 2026 | Carmen Bozic
Officer
|
Sell | 1.7K | $785.3K |
| Jun 1, 2026 | Joy Liu
Officer
|
Sell | 828 | $364.2K |
| May 29, 2026 | Carmen Bozic
Officer
|
Sell | 2.0K | $888.3K |
| May 15, 2026 | Carmen Bozic
Officer
|
Sell | 1.4K | $614.0K |
| May 15, 2026 | Mark E. Bunnage
Officer
|
Sell | 33 | $15.0K |
| May 12, 2026 | Carmen Bozic
Officer
|
Sell | 7.0K | $3.1M |
| May 4, 2026 | Sangeeta N Bhatia
Director
|
Sell | 318 | $134.7K |
| May 1, 2026 | Joy Liu
Officer
|
Sell | 1.1K | $469.2K |
| May 1, 2026 | Sangeeta N Bhatia
Director
|
Grant | 943 | - |
| May 1, 2026 | Alan M Garber
Director
|
Grant | 472 | - |
| May 1, 2026 | Diana L Mckenzie
Director
|
Grant | 943 | - |
| May 1, 2026 | Jennifer J Schneider
Director
|
Grant | 472 | - |
| May 1, 2026 | Nancy A. Thornberry
Director
|
Grant | 472 | - |
| Apr 1, 2026 | Joy Liu
Officer
|
Sell | 978 | $439.3K |
| Mar 27, 2026 | Carmen Bozic
Officer
|
Sell | 2.3K | $1.1M |
| Mar 13, 2026 | Carmen Bozic
Officer
|
Sell | 2.3K | $1.1M |
| Mar 11, 2026 | Duncan J. Mckechnie
Officer
|
Sell | 2.6K | $1.3M |
| Mar 2, 2026 | Joy Liu
Officer
|
Sell | 892 | $442.4K |
| Feb 27, 2026 | Reshma Kewalramani
Chief Executive Officer
|
Sell | 40.0K | $19.7M |
| Feb 27, 2026 | Carmen Bozic
Officer
|
Sell | 2.3K | $1.1M |
| Feb 26, 2026 | Kristen Ambrose
Officer
|
Sell | 357 | $172.6K |
| Feb 25, 2026 | Duncan Mckechnie
Officer
|
Sell | 4.9K | $2.4M |
| Feb 25, 2026 | Amit Sachdev
Officer
|
Sell | 1.8K | $897.8K |
| Feb 25, 2026 | Jonathan Prim Biller
Officer
|
Sell | 945 | $459.6K |
| Feb 25, 2026 | Edward Morrow Atkinson III
Chief Technology Officer
|
Sell | 668 | $324.9K |
| Feb 25, 2026 | Mark E. Bunnage
Officer
|
Sell | 620 | $301.5K |
| Feb 25, 2026 | Ourania Tatsis
Officer
|
Sell | 260 | $126.5K |
| Feb 25, 2026 | Kristen Ambrose
Officer
|
Sell | 223 | $108.5K |
| Feb 19, 2026 | Amit Sachdev
Officer
|
Sell | 58.6K | $27.5M |
| Feb 19, 2026 | Amit Sachdev
Officer
|
Option | 48.5K | $8.3M |
| Feb 18, 2026 | Jonathan Prim Biller
Officer
|
Sell | 3.7K | $1.8M |
| Feb 18, 2026 | Mark E. Bunnage
Officer
|
Sell | 3.6K | $1.8M |
| Feb 18, 2026 | Edward Morrow Atkinson III
Chief Technology Officer
|
Sell | 2.8K | $1.4M |
| Feb 18, 2026 | Kristen Ambrose
Officer
|
Sell | 2.2K | $1.1M |
| Feb 18, 2026 | Ourania Tatsis
Officer
|
Sell | 977 | $472.4K |
| Feb 17, 2026 | Kristen Ambrose
Officer
|
Grant | 1.8K | - |
| Feb 17, 2026 | Edward Morrow Atkinson III
Chief Technology Officer
|
Grant | 5.0K | - |
| Feb 17, 2026 | Jonathan Prim Biller
Officer
|
Grant | 4.1K | - |
| Feb 17, 2026 | Carmen Bozic
Officer
|
Grant | 5.4K | - |
| Feb 17, 2026 | Mark E. Bunnage
Officer
|
Grant | 2.6K | - |
| Feb 17, 2026 | Reshma Kewalramani
Chief Executive Officer
|
Grant | 16.3K | - |
| Feb 17, 2026 | Jeffrey M Leiden
Officer and Director
|
Grant | 8.3K | - |
| Feb 17, 2026 | Duncan Mckechnie
Officer
|
Grant | 5.0K | - |
| Feb 17, 2026 | Amit Sachdev
Officer
|
Grant | 5.8K | - |
| Feb 17, 2026 | Ourania Tatsis
Officer
|
Grant | 5.8K | - |
| Feb 17, 2026 | Charles F Wagner Jr
Chief Operating Officer
|
Grant | 7.4K | - |
| Feb 13, 2026 | Ourania Tatsis
Officer
|
Sell | 1.5K | $750.0K |
| Feb 13, 2026 | Jonathan Prim Biller
Officer
|
Sell | 988 | $493.0K |
| Feb 13, 2026 | Sangeeta N Bhatia
Director
|
Sell | 266 | $133.0K |
| Feb 11, 2026 | Mark E. Bunnage
Officer
|
Sell | 2.0K | $930.5K |
| Feb 11, 2026 | Jonathan Prim Biller
Officer
|
Sell | 1.9K | $886.3K |
| Feb 11, 2026 | Edward Morrow Atkinson III
Chief Technology Officer
|
Sell | 1.8K | $806.2K |
| Feb 11, 2026 | Kristen Ambrose
Officer
|
Sell | 1.4K | $633.6K |
| Feb 11, 2026 | Ourania Tatsis
Officer
|
Sell | 466 | $214.6K |
| Jan 22, 2026 | David Altshuler
Officer
|
Grant | 11.2K | - |
| Jan 22, 2026 | Kristen Ambrose
Officer
|
Grant | 4.3K | - |
| Jan 22, 2026 | Edward Morrow Atkinson III
Chief Technology Officer
|
Grant | 7.8K | - |
| Jan 22, 2026 | Jonathan Prim Biller
Officer
|
Grant | 9.1K | - |
| Jan 22, 2026 | Carmen Bozic
Officer
|
Grant | 11.3K | - |
| Jan 22, 2026 | Reshma Kewalramani
Chief Executive Officer
|
Grant | 38.9K | - |
| Jan 22, 2026 | Jeffrey M Leiden
Officer and Director
|
Grant | 9.0K | - |
| Jan 22, 2026 | Duncan Mckechnie
Officer
|
Grant | 6.8K | - |
| Jan 22, 2026 | Amit Sachdev
Officer
|
Grant | 11.7K | - |
| Jan 22, 2026 | Ourania Tatsis
Officer
|
Grant | 11.7K | - |
| Jan 22, 2026 | Charles F Wagner Jr
Chief Operating Officer
|
Grant | 13.6K | - |
| Jan 7, 2026 | Ourania Tatsis
Officer
|
Sell | 4.5K | $2.1M |
| Jan 6, 2026 | Charles F Wagner Jr
Chief Operating Officer
|
Sell | 9.5K | $4.4M |
| Jan 6, 2026 | Charles F Wagner Jr
Chief Operating Officer
|
Option | 9.5K | $1.8M |
| Dec 4, 2025 | Jeffrey M Leiden
Officer and Director
|
Option | 63.8K | $5.5M |
| Dec 3, 2025 | Jeffrey M Leiden
Officer and Director
|
Sell | 63.8K | $28.7M |
| Dec 3, 2025 | Charles F Wagner Jr
Chief Operating Officer
|
Sell | 14.0K | $6.4M |
| Dec 3, 2025 | Ourania Tatsis
Officer
|
Sell | 4.5K | $2.0M |
| Dec 3, 2025 | Jonathan Prim Biller
Officer
|
Sell | 347 | $155.8K |
| Nov 19, 2025 | Lloyd A Carney
Director
|
Grant | 800 | - |
| Nov 17, 2025 | Edward Morrow Atkinson III
Chief Technology Officer
|
Sell | 2.5K | $1.1M |
| Nov 14, 2025 | Jeffrey M Leiden
Officer and Director
|
Sell | 73.3K | $32.3M |
| Nov 14, 2025 | Jeffrey M Leiden
Officer and Director
|
Option | 73.3K | $6.5M |
| Oct 2, 2025 | Jonathan Prim Biller
Officer
|
Sell | 694 | $280.5K |
| Aug 27, 2025 | Sangeeta N Bhatia
Director
|
Sell | 266 | $102.9K |
| Aug 6, 2025 | Reshma Kewalramani
Chief Executive Officer
|
Buy | 10.0K | $3.9M |
| Aug 6, 2025 | Bruce I Sachs
Director
|
Buy | 5.0K | $1.9M |
| May 15, 2025 | David Altshuler
Officer
|
Sell | 52 | $22.1K |
| May 13, 2025 | Stuart A Arbuckle
Chief Operating Officer
|
Grant | 37.6K | - |
| May 2, 2025 | Sangeeta N Bhatia
Director
|
Sell | 400 | $202.3K |
| May 1, 2025 | Sangeeta N Bhatia
Director
|
Grant | 796 | - |
| May 1, 2025 | Lloyd A Carney
Director
|
Grant | 796 | - |
| May 1, 2025 | Alan M Garber
Director
|
Grant | 398 | - |
| May 1, 2025 | Diana L Mckenzie
Director
|
Grant | 796 | - |
| May 1, 2025 | Jennifer J Schneider
Director
|
Grant | 796 | - |
| May 1, 2025 | Nancy A. Thornberry
Director
|
Grant | 398 | - |
| May 1, 2025 | Suketu P Upadhyay
Director
|
Grant | 796 | - |
Source: TwelveData, from SEC Form 4 filings
VRTX stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.